Novel Agents in Pancreatic Cancer

Video

This video covers the latest research in pancreatic cancer, including the possible role of PARP inhibitors, immunotherapy, and the novel drug PEGPH20.

In this video, Philip A. Philip, MD, PhD, of the Barbara Ann Karmanos Cancer Institute in Detroit, discusses the latest research developments and progress in the treatment of pancreatic cancer.

Philip touches on newer chemotherapy regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel and highlights immunotherapy in this setting and targeted agents such as PARP inhibitors and a novel drug, pegylated recombinant human hyaluronidase (PEGPH20).

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content
Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer

Ariana Pelosci
November 21st 2024
Article

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

Approaching End-of-Life Discussions With Directness and Compassion

Ariana Pelosci
October 30th 2024
Article

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

Adrienne Bruce Shannon, MD;Sean Dineen, MD;Muhammad Talha Waheed, MD
April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.

5-FU Bolus Omission May Reduce Toxicity, Maintain Efficacy in GI Cancers

Russ Conroy
October 14th 2024
Article

Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.

ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers

Russ Conroy
September 26th 2024
Article

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.